Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wow, nice close today, news should be right around the corner.
investor relations, coming out with reverse merger. This will skyrocket
TXHE reverse merger news coming!!!
TXHE! UP UP AND AWAY!
NEXT RESISTANCE .0010! hold them shares!
.0007's on the bid! Getting thin!
Investor Relations, hinting towards Reverse Merger news coming.
Reverse Merger incominggggg!!!!
8-k coming tomorrow morning at 10am. Straight from investor relations, Ricky Bernard.
wow huge buy, 7 million shares
The OTC deadline to report the 2017 Q1 financial report is May 15th.
ACGX should report soon or before that date.
between 2.50 and 2.80 is a great buy. Good Risk/Reward around these levels. Biggest holder sits at 2.50. Also there are requirements in order to be listed on the NASDAQ or NYSE. So.. you can do the math.
Because I reached out to HR and this is what they said:
The objective is to up list either concurrent or shortly after the next round of financing. The company is working on that financing currently and ideally that will happen in the not too distant future. Up listing and completing the financing is absolutely a major priority right now – especially on the back of the positive recent discussions with the FDA regarding their development plans. The meeting with the FDA that was disclosed in early 2017 by press release really validated the development pathway and to a larger degree, their business model as a whole. The FDA is definitely working hard to bring treatments for rare orphan diseases and pediatrics especially to market. That is absolutely a major differentiator with KBIO, they are utilizing FDA incentive programs to accelerate development pathways or also programs which provide additional monetary incentive, such as Priority Review Vouchers, or PRVs for short. I think the street underestimates the potential value that can be created with the lead candidate, benz. They can utilize existing clinical data and will likely be granted an orphan designation – and then also will very likely receive a PRV if the drug is approved and all goes as planned. Those PRVs are fully transferable and have sold from anywhere between $125 mil and $350 mil recently. That would definitely be a game changer. Of course, there is a lot of work to do between here and there, and no assurances can be made, but from a risk-reward perspective it is a very interesting opportunity.
The company has identified several other development opportunities that are similar in nature and will be pursued aggressively when capital is raised. There is a good sized population of opportunities that fit the profile, but a handful of select targets are at the top of the target list to acquire. The company should be able to generate revenues or tangible liquid assets which could be sold within a fairly short timeline as far as the world of biotech goes – that is potentially sometime in early 2017.
Numerous near term share price catalysts –
• PRV – these can even be sold at a discount prior to actually be granted, the company has already had talks with prospective buyers
• Orphan status designation would create value
• Partnering with a strategic to push the secondary candidate forward, lenz
• Up listing to a major exchange
• Acquisition of additional development candidates
Up-listing and financing coming soon. Get ready.
Im short also, there will need to be a pull back and investors will look for a lower entry point. It will fade.
Going up 2-3% is a panic? lol
oh really?
Another Pop at open and then all day short. Same song and dance as yesterday
Feelings mutual there. This turd is just circling the toilet bowl.
Here comes the slaughterhouse. Baggies for days.
I agree, it will start to crack after the day traders are done playing around with this and the hype is gone. Here today, gone tomorrow.
Time to sell. Here comes gravity.
CEO Cameron Durrant weighs in:
https://www.linkedin.com/pulse/kalobios-transformation-underway-dr-cameron-durrant-md-mba?trk=hb_ntf_MEGAPHONE_ARTICLE_POST
Also, website updated:
http://www.kalobios.com
Hang in there.
https://kalobiosbankruptcyreviewed.wordpress.com/
For a better understanding.
Thank you.
Updated their website.
http://kalobios.com
BRISBANE, Calif., April 11, 2016 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (KBIOQ) today announced the adoption of a new pricing model that will guide the company’s strategy and operations. This framework applies to all products in the company’s current and future pipeline, including benznidazole in the potential treatment of Chagas disease.
“Our new pricing model is a commitment to define and develop transparent, responsible pricing for the products we hope to bring to patients in the future,” said Cameron Durrant, MD, MBA, KaloBios’ Chairman and Chief Executive Officer. “Drug pricing is a big concern for all stakeholders in healthcare. We believe that our approach balances the needs of key stakeholders, including patients, clinicians, payers, NGOs, investors, policy makers and advocacy groups.”
KaloBios’ Responsible Pricing Model:
•Responsible Pricing = affordable for patients and payers, transparent for stakeholders and delivers a reasonable return for the company taking the risk of bringing products to patients.
•We plan to price our products at overall cost, plus a reasonable and transparent profit margin, if and when we commercialize them.
•In the case of benznidazole, for instance, the price will be cost plus a modest profit margin. We are not conducting original research on benznidazole and therefore do not plan to incorporate an “R&D premium” into the price.
•We will publicly share the key elements that make up the pricing of our products.
•We will seek input from key stakeholders on what would constitute a reasonable return.
•We will not take arbitrary price increases on our products and will limit any increase to no more than the rate of inflation or Consumer Price Index and to no more than once a year, if at all.
•We will not engage in aggressive or predatory pricing policies or “price-gouging.”
•We plan to ensure patients, irrespective of their ability to pay, will have access to benznidazole, if and when KaloBios commercializes the product for Chagas disease in the United States.
•In developing countries, we plan to make benznidazole available at, or near cost and plan to work with partners on creating access programs to ensure patients in need receive the medication.
KaloBios anticipates sharing additional information related to how it will implement this model over the coming months and years.
About Benznidazole
Benznidazole is an oral anti-parasitic medication used in the treatment of Chagas disease. An estimated 300,000 people in the United States are infected with Chagas disease, which, if left untreated, can lead to serious and potentially life-threatening cardiovascular, gastro-intestinal and neurological complications. Chagas disease can be transmitted via insect vectors, from mother-to-fetus and via blood transfusions or organ transplantation. Benznidazole is the standard of care for Chagas disease but is not currently approved by the U.S. Food and Drug Administration (FDA) and is available in the United States only from the Centers for Disease Control and Prevention (CDC) under investigational protocols.
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. (KBIOQ) is a developmental stage, biopharmaceutical company focused on advancing treatments for neglected diseases. On Dec. 29, 2015, KaloBios filed a voluntary petition for bankruptcy protection under Chapter 11 of Title 11 of the United States Bankruptcy Code, and currently manages and operates its business and assets as a "debtor-in-possession.” KaloBios is working to emerge from bankruptcy.
Forward-Looking Statements
This release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, Bankruptcy Court approval for the Company to continue its operations; the Company’s ability to manage expenses and fund its working capital needs during the Chapter 11 process; the Company’s ability to manage its relationships with its creditors, vendors, and customers during the Chapter 11 process; the Company’s ability to emerge from bankruptcy successfully; the Company’s access to limited cash reserves and its ability to obtain additional capital on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that the Company has initiated or plans to initiate; the potential timing and outcomes of clinical studies of benznidazole, lenzilumab, KB004 or any other products undertaken now or in the future; the Company’s ability to consummate the acquisition of rights to benznidazole; the commercial viability of the Company’s proposed drug pricing program; the ability of the Company to timely source adequate supply of its development products from third party manufacturers on whom the Company depends; the potential, if any, for future development of any of its present or future products; the Company's ability to successfully progress, partner or complete further development of its programs; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; the Company's ability to protect the Company's intellectual property; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and other factors listed under "Risk Factors" in the Company's most recent quarterly report on Form 10-Q filed with the Securities and Exchange Commission on August 10, 2015, the Annual Report on Form 10-K filed on March 16, 2015, and the Company's other filings with the Securities and Exchange Commission.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The company has no obligation, and expressly disclaims any obligation to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Media Contact:
Lisa Guiterman
(202) 330-3431
media@kalobios.com
The single most material contingency remaining unknown — as to whether KaloBios will be able to adroitly exit Chapter 11 by mid-June 2016, and thus remain in position to execute on the Savant Chagas drug candidate deal — is the timely securing of the DiP financing package.
As earlier indicated, today is the final deadline for signing the bid process, and stalking horse financing proposal documents — put forward by Black Horse Capital, and approved as to form by the court.
We have seen no evidence of signatures yet, try checking throughout the day, at the court’s electronic docket, and the SEC EDGAR window.
Hopefully there will be an update with any news soon.
Of course, without the potential $320 million from the FDA PRV — out of the eventual successful completion of the Savant Chagas deal — none of this matters. KaloBios was nearly extinct before it, and will be extinct without it.
So do stay tuned.
https://kalobiosbankruptcyreviewed.wordpress.com/
Very quiet today.
Goooood Morning,
Will the definitive agreement get signed today for Black Horse Capitol for the $10-13 million in financing? Deadline is tomorrow.
We shall see.
We will see how the hearing turns out by the price action at the end of the day. Also, it should be interesting to read the court dockets tomorrow, regardless if there's no news.
That's the unknown.
Read this. A couple ideas in there.
https://kalobiosbankruptcyreviewed.wordpress.com/2016/03/11/bidding-procedures-for-dip-financing-with-stalking-horse-proposal-available/#comments
I agree.
These PIPE investors are a joke.
Section 510(b) of the Code permits this, so long as the PIPE claimants possessed a “factual nexus” to the purchase of debtor’s (KaloBios) securities. So — even if the PIPE Group shows that the December 2015 deal never fully closed, they did in fact enter into negotiations, and transfer money directly to KaloBios (there was no third party escow holder, apparently), expecting to reap a return. And this part is critical — a return on equity. Not a fixed debt, nor an interest payment — no, a (potentially) unlimited upside in price appreciation, from their equity. Arguably that makes Code Section 510(b) subordination available to the debtor — here, KaloBios.
So — my bet is now that KaloBios will get its DiP financing done for $10-$13 million, retain the PIPE money (for now), and pay the December 2015 PIPE Group some portion back in cash, on exit from bankruptcy — all while granting them essentially what they originally expected — at least some equity participation in the hoped-for riches from an FDA priority review voucher, long post exit.
Hopefully this settles today at the hearing and the restructuring plan for exiting bankruptcy gets approved along with the definitive stalking horse agreement for the $10-$13 million in financing.
We shall see.
The hearing isn't scheduled until 2 PM EDT in Delaware today. No news will be out, if anything until later on today or tomorrow.
With a small float like KBIOQ and the possibility of positive news on the horizon, anything can happen in OTC land, even your "gut feeling" can come true.
I agree. We shall see what happens this week since there is a lot in play. With the hearing tomorrow possibly about the lawsuit and reorganizational plan and also with the deadline for the financing on Thursday, we may see a rise in PPS in anticipation with the optimistic investors leading up to these points in time.
The PIPE investors are probably happy about the per share price increase in KBIOQ… But if my memory is correct their cost basis is $20 or more. We could see that in the near future. We shall see.
I was referring to everyone that knows the deal here.
In reference to everyone that bought.
Not everyone else who hasn't bought.
I was only talking about the individuals that make up the volume.
Although its not much, they most likely have the same thought process for what is taking place this week.
Expecting a press release this week sometime after tomorrows hearing?
-April 5, 2016 hearing has been scheduled for 2 PM EDT in Delaware, hopefully approve Chapter 11 plan and disclosure statement and settle the claims of the PIPE Group.
-April 7 is the deadline to have the definitive stalking horse deal signed for $10-$13 million.
https://kalobiosbankruptcyreviewed.wordpress.com/
Will it be a green, positive week? One can not be for sure but it's certainly off to a good start.